Yin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yin Wang has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Peng Lin
School of Life Sciences, Westlake University, 310024, Hangzhou, China
21 shared publications - Qi Xie
Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, Zhejiang, China; School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang, China
21 shared publications - Chen Guo
Westlake Disease Modeling Laboratory, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China
19 shared publications - Chengfang Sun
Department of Urology, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China
19 shared publications - Chongran Sun
Medical School, Department of Neurosurgery of 2nd Affiliated Hospital of Zhejiang University, Hangzhou, China
19 shared publications - Chun Wang
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
19 shared publications
Latest Publications
- 20 February 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (11) , 3032-3048
Angiotensin‐(1–9) attenuates diabetic cardiomyopathy by improving insulin resistance
Background and Purpose: Diabetic cardiomyopathy is a clinical condition of ventricular dysfunction, with obesity and insulin resistance as the primary risk factors. Under this condition, the heart encounters lipotoxicity, which impairs cardiac insulin sensitivity and leads to cardiomyopathy. Angiotensin‐(1–9) is a peptide of the counter‐regulatory axis of the renin‐angiotensin system with cardioprotective effects. However, its role in diabetic cardiomyopathy is unknown. Experimental Approach: To investigate the role of angiotensin‐(1–9), we first induced lipotoxic stress in the heart by high‐fat diet (HFD) feeding in mice. Angiotensin‐(1–9) was then administered for 4 weeks using osmotic mini‐pumps. Cardiac function was assessed, and insulin sensitivity was evaluated in heart tissues after insulin bolus injection. Moreover, lipotoxic stress in vitro was modelled by high glucose medium plus palmitate in neonatal rat ventricular myocytes (NRVMs). Key Results: Angiotensin‐(1–9) improves myocardial function and reverts pathological cardiac remodelling under HFD feeding in mice. Moreover, angiotensin‐(1–9) enhances whole‐body glucose tolerance and reduces homeostatic model assessment of insulin resistance (HOMA‐IR). We demonstrate that angiotensin‐(1–9) increases insulin sensitivity in the heart and skeletal muscle but not in adipose tissue or the liver. Mechanistically, angiotensin‐(1–9) does not affect insulin signalling in cardiomyocytes at baseline, whereas it significantly improves insulin action under lipotoxic stress through AT 2 receptors and protein kinase A. Conclusion and Implications: These findings demonstrate that angiotensin‐(1–9) improves cardiac function under metabolic challenge and promotes insulin signalling in cardiomyocytes under lipotoxicity, which may shed light on the therapeutic exploration against diabetic cardiomyopathy.
- 20 February 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (11) , 3032-3048
Angiotensin‐(1–9) attenuates diabetic cardiomyopathy by improving insulin resistance
Background and Purpose: Diabetic cardiomyopathy is a clinical condition of ventricular dysfunction, with obesity and insulin resistance as the primary risk factors. Under this condition, the heart encounters lipotoxicity, which impairs cardiac insulin sensitivity and leads to cardiomyopathy. Angiotensin‐(1–9) is a peptide of the counter‐regulatory axis of the renin‐angiotensin system with cardioprotective effects. However, its role in diabetic cardiomyopathy is unknown. Experimental Approach: To investigate the role of angiotensin‐(1–9), we first induced lipotoxic stress in the heart by high‐fat diet (HFD) feeding in mice. Angiotensin‐(1–9) was then administered for 4 weeks using osmotic mini‐pumps. Cardiac function was assessed, and insulin sensitivity was evaluated in heart tissues after insulin bolus injection. Moreover, lipotoxic stress in vitro was modelled by high glucose medium plus palmitate in neonatal rat ventricular myocytes (NRVMs). Key Results: Angiotensin‐(1–9) improves myocardial function and reverts pathological cardiac remodelling under HFD feeding in mice. Moreover, angiotensin‐(1–9) enhances whole‐body glucose tolerance and reduces homeostatic model assessment of insulin resistance (HOMA‐IR). We demonstrate that angiotensin‐(1–9) increases insulin sensitivity in the heart and skeletal muscle but not in adipose tissue or the liver. Mechanistically, angiotensin‐(1–9) does not affect insulin signalling in cardiomyocytes at baseline, whereas it significantly improves insulin action under lipotoxic stress through AT 2 receptors and protein kinase A. Conclusion and Implications: These findings demonstrate that angiotensin‐(1–9) improves cardiac function under metabolic challenge and promotes insulin signalling in cardiomyocytes under lipotoxicity, which may shed light on the therapeutic exploration against diabetic cardiomyopathy.
- Open Access
- 3 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (9) , 1098-1110
Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis
Background and Aims: Osimertinib is a third-generation tyrosine kinase inhibitor targeting activating mutations of epidermal growth factor receptor with remarkable therapeutic efficacy against non-small cell lung carcinoma. However, its use has been limited by associated cardiotoxicity, primarily with heart failure. Herein, this study aims to better understand the mechanisms underlying osimertinib cardiotoxicity and explore cardioprotective strategies. Methods: This study leverages an in vitro model of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and a clinically relevant in vivo mouse model of osimertinib cardiotoxicity by co-employing transverse aortic constriction to mimic haemodynamic stress in cancer patients. Results: Osimertinib treatment leads to significant contractile dysfunction in mice without cell death, inflammation, or fibrosis. By leveraging single-nucleus RNA sequencing of mouse heart tissues and in vitro assays of human iPSC-CMs, the study reveals significant downregulation of MYLK3 and a subsequent decrease in MYL2 phosphorylation with marked sarcomere disarray as the main mechanism of osimertinib cardiotoxicity. GATA4 is further identified as a putative target of osimertinib, connecting its decreased phosphorylation to repressed MYLK3 transcription. The reversibility of osimertinib-induced cardiac dysfunction upon discontinuation of osimertinib treatment supports the hypothesis that transient sarcomere disruption, rather than permanent cellular damage, serves as the key underlying mechanism. Finally, the myosin activator omecamtiv is shown to be effective in preventing osimertinib cardiotoxicity. Conclusions: These findings suggest that osimertinib causes reversible cardiac dysfunction by disrupting MYL2 phosphorylation via GATA4 dephosphorylation-mediated suppression of MYLK3 and highlight the potential of myosin activation as a preventive or rescue strategy for osimertinib cardiotoxicity.
- 3 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (9) , 1098-1110
Open AccessOsimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis
Background and Aims: Osimertinib is a third-generation tyrosine kinase inhibitor targeting activating mutations of epidermal growth factor receptor with remarkable therapeutic efficacy against non-small cell lung carcinoma. However, its use has been limited by associated cardiotoxicity, primarily with heart failure. Herein, this study aims to better understand the mechanisms underlying osimertinib cardiotoxicity and explore cardioprotective strategies. Methods: This study leverages an in vitro model of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and a clinically relevant in vivo mouse model of osimertinib cardiotoxicity by co-employing transverse aortic constriction to mimic haemodynamic stress in cancer patients. Results: Osimertinib treatment leads to significant contractile dysfunction in mice without cell death, inflammation, or fibrosis. By leveraging single-nucleus RNA sequencing of mouse heart tissues and in vitro assays of human iPSC-CMs, the study reveals significant downregulation of MYLK3 and a subsequent decrease in MYL2 phosphorylation with marked sarcomere disarray as the main mechanism of osimertinib cardiotoxicity. GATA4 is further identified as a putative target of osimertinib, connecting its decreased phosphorylation to repressed MYLK3 transcription. The reversibility of osimertinib-induced cardiac dysfunction upon discontinuation of osimertinib treatment supports the hypothesis that transient sarcomere disruption, rather than permanent cellular damage, serves as the key underlying mechanism. Finally, the myosin activator omecamtiv is shown to be effective in preventing osimertinib cardiotoxicity. Conclusions: These findings suggest that osimertinib causes reversible cardiac dysfunction by disrupting MYL2 phosphorylation via GATA4 dephosphorylation-mediated suppression of MYLK3 and highlight the potential of myosin activation as a preventive or rescue strategy for osimertinib cardiotoxicity.
- Open Access
- 8 November 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (24) , 6336-6363
Nuclear receptor E75/NR1D2 promotes tumor malignant transformation by integrating Hippo and Notch pathways
Hormone therapy resistance and the ensuing aggressive tumor progression present a significant clinical challenge. However, the mechanisms underlying the induction of tumor malignancy upon inhibition of steroid hormone signaling remain poorly understood. Here, we demonstrate that Drosophila malignant epithelial tumors show a similar reduction in ecdysone signaling, the main steroid hormone pathway. Our analysis of ecdysone-induced downstream targets reveals that overexpression of the nuclear receptor E75, particularly facilitates the malignant transformation of benign tumors. Genome-wide DNA binding profiles and biochemistry data reveal that E75 not only binds to the transcription factors of both Hippo and Notch pathways, but also exhibits widespread co-binding to their target genes, thus contributing to tumor malignancy. We further validated these findings by demonstrating that depletion of NR1D2 , the mammalian homolog of E75, inhibits the activation of Hippo and Notch target genes, impeding glioblastoma progression. Together, our study unveils a novel mechanism by which hormone inhibition promotes tumor malignancy, and describes an evolutionarily conserved role of the oncogene E75/NR1D2 in integration of Hippo and Notch pathway activity during tumor progression.
- 8 November 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (24) , 6336-6363
Open AccessNuclear receptor E75/NR1D2 promotes tumor malignant transformation by integrating Hippo and Notch pathways
Hormone therapy resistance and the ensuing aggressive tumor progression present a significant clinical challenge. However, the mechanisms underlying the induction of tumor malignancy upon inhibition of steroid hormone signaling remain poorly understood. Here, we demonstrate that Drosophila malignant epithelial tumors show a similar reduction in ecdysone signaling, the main steroid hormone pathway. Our analysis of ecdysone-induced downstream targets reveals that overexpression of the nuclear receptor E75, particularly facilitates the malignant transformation of benign tumors. Genome-wide DNA binding profiles and biochemistry data reveal that E75 not only binds to the transcription factors of both Hippo and Notch pathways, but also exhibits widespread co-binding to their target genes, thus contributing to tumor malignancy. We further validated these findings by demonstrating that depletion of NR1D2 , the mammalian homolog of E75, inhibits the activation of Hippo and Notch target genes, impeding glioblastoma progression. Together, our study unveils a novel mechanism by which hormone inhibition promotes tumor malignancy, and describes an evolutionarily conserved role of the oncogene E75/NR1D2 in integration of Hippo and Notch pathway activity during tumor progression.
- Open Access
Nuclear receptor E75/NR1D2 drives tumor malignant transformation by integrating Hippo and Notch pathways
Hormone therapy resistance and the ensuing aggressive progression of tumors present a significant clinical challenge. However, the mechanisms underlying the induction of tumor malignancy by hormone inhibition remain poorly understood. Here we show that Drosophila malignant epithelial tumors exhibit a comparable decrease in ecdysone signaling, the primary steroid hormone pathway in Drosophila . Furthermore, we find that ectopic expression of the nuclear receptor E75 partially mimics ecdysone signaling inhibition, specifically promoting the malignant transformation of benign tumors by integrating the Hippo and Notch signaling pathways. Genome-wide DNA binding profiles and biochemistry data reveal that E75 not only physically interacts with the transcription factors of both Hippo and Notch pathways, but also exhibits widespread co-binding to their target genes, thus contributing to tumor malignancy. Moreover, we validate these findings by demonstrating that depletion of NR1D2 , the mammalian equivalent of E75, inhibits the activation of Hippo and Notch target genes, impeding glioblastoma progression in vivo . In summary, our study unveils a previously unrecognized mechanism by which hormone inhibition promotes tumor malignant transformation, while providing a conserved mechanistic understanding of how Hippo and Notch pathways are integrated by the oncogene E75/NR1D2 during tumor progression.
Open AccessNuclear receptor E75/NR1D2 drives tumor malignant transformation by integrating Hippo and Notch pathways
Hormone therapy resistance and the ensuing aggressive progression of tumors present a significant clinical challenge. However, the mechanisms underlying the induction of tumor malignancy by hormone inhibition remain poorly understood. Here we show that Drosophila malignant epithelial tumors exhibit a comparable decrease in ecdysone signaling, the primary steroid hormone pathway in Drosophila . Furthermore, we find that ectopic expression of the nuclear receptor E75 partially mimics ecdysone signaling inhibition, specifically promoting the malignant transformation of benign tumors by integrating the Hippo and Notch signaling pathways. Genome-wide DNA binding profiles and biochemistry data reveal that E75 not only physically interacts with the transcription factors of both Hippo and Notch pathways, but also exhibits widespread co-binding to their target genes, thus contributing to tumor malignancy. Moreover, we validate these findings by demonstrating that depletion of NR1D2 , the mammalian equivalent of E75, inhibits the activation of Hippo and Notch target genes, impeding glioblastoma progression in vivo . In summary, our study unveils a previously unrecognized mechanism by which hormone inhibition promotes tumor malignant transformation, while providing a conserved mechanistic understanding of how Hippo and Notch pathways are integrated by the oncogene E75/NR1D2 during tumor progression.
- Open Access
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary table 2 from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Supplementary table 2 from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 2 from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Supplementary table 2 from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
- Open Access
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Isocitrate dehydrogenase (IDH)–wild-type (WT) high-grade gliomas, especially glioblastomas, are highly aggressive and have an immunosuppressive tumor microenvironment. Although tumor-infiltrating immune cells are known to play a critical role in glioma genesis, their heterogeneity and intercellular interactions remain poorly understood. In this study, we constructed a single-cell transcriptome landscape of immune cells from tumor tissue and matching peripheral blood mononuclear cells (PBMC) from IDH-WT high-grade glioma patients. Our analysis identified two subsets of tumor-associated macrophages (TAM) in tumors with the highest protumorigenesis signatures, highlighting their potential role in glioma progression. We also investigated the T-cell trajectory and identified the aryl hydrocarbon receptor (AHR) as a regulator of T-cell dysfunction, providing a potential target for glioma immunotherapy. We further demonstrated that knockout of AHR decreased chimeric antigen receptor (CAR) T-cell exhaustion and improved CAR T-cell antitumor efficacy both in vitro and in vivo. Finally, we explored intercellular communication mediated by ligand–receptor interactions within the tumor microenvironment and PBMCs and revealed the unique cellular interactions present in the tumor microenvironment. Taken together, our study provides a comprehensive immune landscape of IDH-WT high-grade gliomas and offers potential drug targets for glioma immunotherapy.
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Isocitrate dehydrogenase (IDH)–wild-type (WT) high-grade gliomas, especially glioblastomas, are highly aggressive and have an immunosuppressive tumor microenvironment. Although tumor-infiltrating immune cells are known to play a critical role in glioma genesis, their heterogeneity and intercellular interactions remain poorly understood. In this study, we constructed a single-cell transcriptome landscape of immune cells from tumor tissue and matching peripheral blood mononuclear cells (PBMC) from IDH-WT high-grade glioma patients. Our analysis identified two subsets of tumor-associated macrophages (TAM) in tumors with the highest protumorigenesis signatures, highlighting their potential role in glioma progression. We also investigated the T-cell trajectory and identified the aryl hydrocarbon receptor (AHR) as a regulator of T-cell dysfunction, providing a potential target for glioma immunotherapy. We further demonstrated that knockout of AHR decreased chimeric antigen receptor (CAR) T-cell exhaustion and improved CAR T-cell antitumor efficacy both in vitro and in vivo. Finally, we explored intercellular communication mediated by ligand–receptor interactions within the tumor microenvironment and PBMCs and revealed the unique cellular interactions present in the tumor microenvironment. Taken together, our study provides a comprehensive immune landscape of IDH-WT high-grade gliomas and offers potential drug targets for glioma immunotherapy.